Pernix Therapeutics Holdings Inc : Pernix Therapeutics to Report Second Quarter 2012 Financial Results on August 14, 2012
08/02/2012| 10:35am US/Eastern
Management to Host a Conference Call on August 14 at 9:00 a.m. EDT
Pernix Therapeutics Holdings, Inc. (NYSE MKT: PTX), a specialty
pharmaceutical company, today announced that it will release its second
quarter 2012 financial results before the U.S. stock market opens on
Tuesday, August 14, 2012 and has scheduled a conference call at 9:00 am
EDT that day to discuss the financial results.
The conference call will feature remarks by Cooper Collins, Chief
Executive Officer, and David Becker, Chief Financial Officer. To
participate in the conference call, please dial (877) 874-1565
(domestic) or (719) 325-4751 (international). Participants can reference
the passcode 4635735. Please dial in approximately 5 minutes prior to
The conference call will also be available via a live listen-only
webcast and can be accessed through the Investor Relations section of
the Company's website, www.pernixtx.com.
Please allow extra time prior to the call to visit the Company's website
and download any software that may be needed to listen to the webcast.
A replay of the conference call will be available through August 21,
2012, at (888) 203-1112 (domestic) or (719) 457-0820 (international).
The passcode for the replay is 4635735. An online archive of the webcast
will be available on the Company's website for 30 days following the
About Pernix Therapeutics Holdings, Inc.
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company
primarily focused on the sales, marketing, and development of branded,
generic and OTC pharmaceutical products. The Company manages a portfolio
of branded and generic products. The Company's branded products for the
pediatrics market include CEDAX®, an antibiotic for middle ear
infections, NATROBA?, a topical treatment for head lice marketed under
an exclusive co-promotion agreement with ParaPRO, LLC, and a family of
prescription treatments for cough and cold (BROVEX®, ALDEX® and
PEDIATEX®). The Company's branded products for the gastroenterology
market include OMECLAMOX-PAK®, a ten-day therapy of omeprazole
delayed-release capsules, clarithromycin tablets and amoxicillin
capsules for the treatment of Helicobacter pylori infection and duodenal
ulcer disease and REZYST?, a probiotic blend to promote dietary
management. The Company promotes its branded pediatric products through
its sales force. Pernix also markets generic products through its
wholly-owned subsidiary, Macoven Pharmaceuticals. A product candidate
utilizing cough-related intellectual property, is in development for the
U.S. OTC market. Founded in 1996, the Company is based in The Woodlands,
Additional information about Pernix is available on the Company's
website located at www.pernixtx.com.
Pernix Therapeutics Holdings, Inc.
Joseph T. Schepers, Director,
Investor Relations, 800-793-2145 ext. 3002
© Business Wire 2012